HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Consumer Product Recalls: Eye Wash, Chewable Aspirin Recalls

This article was originally published in The Pink Sheet

Executive Summary

OTC eye washes distributed under Family Care, Major and Rugby brands, and HealthA2Z aspirin are recalled.

You may also be interested in...



Pipeline Watch: 11 Approvals And Eight Phase III Trial Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Worsening UK Pharma Sector Close To ‘Tipping Point,’ Warns GSK Chief

Dame Emma Walmsley has delivered a broadside to the UK government, urging it to reverse a raised revenues ‘clawback’ for pharma companies and boost new medicines uptake in order to maintain the UK’s competitiveness in life sciences.

Sanofi Consumer Healthcare Reaches 'Next Level Of Autonomy'

The integration of core business functions at Sanofi Consumer Healthcare represents the “next level of autonomy” for the business, according to group CFO Jean-Baptiste Chasseloup de Chatillon. “As a result, you can expect a much enhanced CHC disclosure, allowing you easy peer comparisons and our team benchmark will be easier and more compelling.” The move came as Sanofi Consumer Healthcare reported a strong end to 2022, with Q4 sales up by 6.6% at constant exchange rates to €1.22bn. 

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS122770

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel